Timothy Jackson, MD
Internal Medicine · Beaver, PANPI 1427070747
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 30.3% of the total. Reporting peaked in 2019 at $260 and has fallen 58.0% since, to $109 in 2025.
Across 63 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$315
- AbbVie$160
- GSK$124
- Astellas Pharma US Inc$73
- Johnson & Johnson$68
- Pfizer$63
- plus $236 from 11 others
Across 597 payments — averaging $2648.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.1M
- Chiesi USA, Inc.$109K
- Novo Nordisk AS$102K
- Pfizer$78K
- Avanir Pharmaceuticals, Inc.$72K
- Bayer$47K
- plus $117K from 4 others
What the payments were for
- Food & beverage$1,00797%
- Education$333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $315 |
| AbbVie | 8 | $160 |
| GSK | 8 | $124 |
| Astellas Pharma US Inc | 5 | $73 |
| Johnson & Johnson(2 entities) | 5 | $68 |
| Pfizer | 4 | $63 |
| AstraZeneca | 4 | $48 |
| Novartis | 3 | $38 |
| Recor Medical Inc | 1 | $28 |
| Abbott | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$1,040 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 422 | $291,895 |
| OzempicSemaglutide | 172 | $214,557 |
| JardianceEmpagliflozin | 104 | $105,647 |
| XareltoRivaroxaban | 130 | $103,756 |
| MounjaroTirzepatide | 33 | $42,776 |
| JanuviaSitagliptin Phosphate | 32 | $41,172 |
| MyrbetriqMirabegron | 73 | $40,266 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $38,379 |
| XifaxanRifaximin | 12 | $35,431 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $27,682 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $24,405 |
| RexultiBrexpiprazole | 13 | $19,770 |
| TradjentaLinagliptin | 25 | $19,661 |
| TrulicityDulaglutide | 13 | $18,558 |
| EntrestoSacubitril/Valsartan | 20 | $16,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $63 | $291,895422 claims |
| Novo NordiskOzempic | $315 | $214,557172 claims |
| Johnson & JohnsonXarelto | $68 | $103,756130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $16 | $61,33446 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $124 | $51,10880 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $40,26673 claims |
| AbbVieLumigan, Synthroid | $160 | $16,977184 claims |
| NovartisEntresto | $38 | $16,85720 claims |
| AstraZenecaFarxiga | $48 | $13,98622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Beaver
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.